緑内障治療薬の世界市場規模調査・予測：薬剤クラス別、疾患適応別、流通チャネル別、地域別分析、2022-2029年

緑内障治療薬とは、原発性閉塞隅角（PAC）緑内障および原発性開放隅角（POA）緑内障に対する様々な代替治療法を指します。

緑内障は、視神経の構造変化によって引き起こされ、失明や視野欠損につながることが多い疾患です。緑内障の治療を開始するには、主にβ遮断薬、プロスタグランジンアナログ、コリン作動薬、炭酸脱水酵素阻害薬、αアドレナリン作動薬などを含む外用点眼薬が使用されます。これらの点眼薬は、目の中で発生する液体の量を減らし、眼圧（IOP）を低下させます。埋め込み型徐放性デバイス、薬剤溶出性穿刺プラグ、ポリマーベースコンタクトレンズ、マイクロニードル注入デバイス、マイクロドージング技術などのデバイスの使用に続いて、従来の外科手術またはレーザー手術、あるいはその両方の組み合わせが行われることがあります。市場の成長を促す主な要因の1つは、世界的に緑内障の発生率が上昇していることです。糖尿病や加齢黄斑変性症（AMD）、白内障、ドライアイなどの眼疾患を持つ患者は、緑内障を発症する確率が非常に高くなります。また、眼科領域における技術の進歩も市場拡大の要因であり、製品の革新や開発が進むことで、市場の需要が高まると予想されます。

緑内障治療薬の世界市場の成長を促進すると予測される主な要因は、失明の発生件数の増加と緑内障患者数の増加です。国際失明予防協会の報告によると、2020年には8000万人が緑内障に罹患し、2010年のデータ調査結果から約2000万人増加するとされています。また、老年人口の増加により、予測期間中に市場にとって有利な機会が生まれると予想されています。しかし、大手企業による薬剤回収が、2022年から2029年の予測期間を通じて市場の成長を抑制しました。

緑内障治療薬の世界市場調査において考慮した主要地域は、アジア太平洋地域、北米、欧州、中南米、その他の世界地域です。北米は、医療インフラの充実と緑内障の有病率の上昇により、市場シェアの点で世界的に優位な地域となっています。一方、アジア太平洋地域は、糖尿病の有病率の上昇、眼疾患の増加、失明者や視覚障害者の増加などの要因により、予測期間中に最高の成長率を示すと予想され、アジア太平洋地域全体で緑内障治療薬市場に有利な成長の見通しを生み出します。

本調査の目的は、近年における様々なセグメントと国の市場規模を定義し、今後数年間の値を予測することです。本レポートは、調査対象国における産業の質的・量的側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細な情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場の潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

• 市場スナップショット
• 世界・セグメント別市場推定・予測、2019年～2029年
  • 緑内障治療薬市場：地域別、2019年～2029年
  • 緑内障治療薬市場（薬物クラス別）：2019-2029年
  • 緑内障治療薬市場：疾患適応症別、2019年-2029年
  • 緑内障治療薬市場：流通チャネル別、2019年～2029年
• 主な動向
• 調査手法
• 調査前提条件

第2章 緑内障治療薬の世界市場定義と範囲

• 調査の目的
• 市場の定義と範囲
  • 調査対象範囲
  • 産業の進化
• 調査対象年
• 通貨換算レート

第3章 世界の緑内障治療薬市場力学

• 緑内障治療薬市場のインパクト分析（2019年～2029年）
  • 市場促進要因
    • 緑内障の罹患率の上昇
    • 技術的進歩の増加
  • 市場の課題
    • 主要プレイヤー別医薬品回収
  • 市場機会
    • 老年人口の増加

第4章 緑内障治療薬の世界市場産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
• PEST分析
  • 政治的
  • 経済的
  • 社会的
  • 技術的
• トップ投資機会
• 主要成功戦略
• 業界専門家別展望
• アナリストの結論・提言

第5章 リスクアセスメント：COVID-19のインパクト

• COVID-19が業界に与える全体的な影響の評価
• COVID-19以前とCOVID-19以後の市場シナリオ

第6章 緑内障治療薬の世界市場：薬物クラス別

• 市場スナップショット
• 緑内障治療薬の世界市場：薬物クラス別、業績-ポテンシャル分析
• 緑内障治療薬の世界市場、ドラッグクラス別推定・予測（2019-2029年
• 緑内障治療薬市場、サブセグメント分析
  • ベータブロッカー
  • プロスタグランジンアナログ
  • αアドレナリン作動薬
  • 炭酸脱水酵素阻害剤
  • 併用薬

第7章 緑内障治療薬の世界市場：疾患適応症別

• 市場スナップショット
• 緑内障治療薬の世界市場：疾患適応症別、性能-潜在能力分析
• 緑内障治療薬の世界市場、疾患適応症別推定・予測2019～2029年
• 緑内障治療薬市場、サブセグメント分析
  • 開放隅角緑内障
  • 閉塞隅角緑内障

第8章 緑内障治療薬の世界市場、流通チャネル別

• 市場スナップショット
• 緑内障治療薬の世界市場：流通チャネル別、実績と可能性分析
• 緑内障治療薬の世界市場、流通チャネル別推定・予測（2019-2029年
• 緑内障治療薬市場、サブセグメント分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 緑内障治療薬の世界市場：地域別分析

• 緑内障治療薬市場、地域別市場スナップショット
• 北米
  • 米国
    • 薬剤クラス別の推定・予測、2019-2029年
    • 疾患適応症別の推定・予測、2019年～2029年
    • 販売チャネル別の推定・予測、2019年～2029年
  • カナダ
• 欧州緑内障治療薬市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他の欧州地域
• アジア太平洋地域の緑内障治療薬市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカの緑内障治療薬市場スナップショット
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ地域
• 世界のその他の地域

第10章 競合情報

• トップ市場戦略
• 企業プロファイル
  • Deep Dive
    • 主要情報
    • 概要
    • 財務情報（データの入手状況により異なります）
    • 製品概要
    • 最近の動向
  • Allergan Plc
  • Merck & Co., Inc.
  • Akorn, Operating Company LLC
  • Bausch & Lomb Incorporated
  • Oculis S.A.
  • Teva Pharmaceuticals Industries Ltd
  • Alcon
  • Pfizer Inc
  • Nanodropper, Inc.

第11章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • バリデーション
  • 出版
• 調査属性
• 調査の前提条件

LIST OF TABLES

• TABLE 1. Global Glaucoma Therapeutics Market, report scope
• TABLE 2. Global Glaucoma Therapeutics Market estimates & forecasts by Region 2019-2029 (USD Billion)
• TABLE 3. Global Glaucoma Therapeutics Market estimates & forecasts by Drug Class 2019-2029 (USD Billion)
• TABLE 4. Global Glaucoma Therapeutics Market estimates & forecasts by Disease Indication 2019-2029 (USD Billion)
• TABLE 5. Global Glaucoma Therapeutics Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
• TABLE 6. Global Glaucoma Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 7. Global Glaucoma Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 8. Global Glaucoma Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 9. Global Glaucoma Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 10. Global Glaucoma Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 11. Global Glaucoma Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 12. Global Glaucoma Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 13. Global Glaucoma Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 14. Global Glaucoma Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 15. Global Glaucoma Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 16. U.S. Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 17. U.S. Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 18. U.S. Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 19. Canada Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 20. Canada Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 21. Canada Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 22. UK Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 23. UK Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 24. UK Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 25. Germany Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 26. Germany Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 27. Germany Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 28. France Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 29. France Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 30. France Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 31. Italy Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 32. Italy Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 33. Italy Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 34. Spain Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 35. Spain Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 36. Spain Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 37. RoE Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 38. RoE Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 39. RoE Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 40. China Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 41. China Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 42. China Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 43. India Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 44. India Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 45. India Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 46. Japan Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 47. Japan Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 48. Japan Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 49. South Korea Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 50. South Korea Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 51. South Korea Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 52. Australia Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 53. Australia Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 54. Australia Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 55. RoAPAC Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 56. RoAPAC Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 57. RoAPAC Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 58. Brazil Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 59. Brazil Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 60. Brazil Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 61. Mexico Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 62. Mexico Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 63. Mexico Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 64. RoLA Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 65. RoLA Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 66. RoLA Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 67. Row Glaucoma Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 68. Row Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 69. Row Glaucoma Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 70. List of secondary sources, used in the study of global Glaucoma Therapeutics Market
• TABLE 71. List of primary sources, used in the study of global Glaucoma Therapeutics Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

• FIG 1. Global Glaucoma Therapeutics Market, research methodology
• FIG 2. Global Glaucoma Therapeutics Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Glaucoma Therapeutics Market, key trends 2021
• FIG 5. Global Glaucoma Therapeutics Market, growth prospects 2022-2029
• FIG 6. Global Glaucoma Therapeutics Market, porters 5 force model
• FIG 7. Global Glaucoma Therapeutics Market, pest analysis
• FIG 8. Global Glaucoma Therapeutics Market, value chain analysis
• FIG 9. Global Glaucoma Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 10. Global Glaucoma Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 11. Global Glaucoma Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 12. Global Glaucoma Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 13. Global Glaucoma Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 14. Global Glaucoma Therapeutics Market, regional snapshot 2019 & 2029
• FIG 15. North America Glaucoma Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 16. Europe Glaucoma Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 17. Asia pacific Glaucoma Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 18. Latin America Glaucoma Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 19. Global Glaucoma Therapeutics Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Glaucoma Therapeutics Market is valued at approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Glaucoma therapeutics refers to the various alternative treatments for Primary Angle-Closure (PAC) and Primary Open-Angle (POA) glaucoma. The condition is caused by structural changes in the optic nerves, which frequently lead to blindness and vision loss. Topical eye drops that primarily include beta-blockers, prostaglandin analogues, cholinergic, carbonic anhydrase inhibitors, and alpha-adrenergic agonists can be used to start the treatment for glaucoma. These eye drops decrease the amount of fluid generated in the eyes, reducing intraocular pressure (IOP). The usage of devices such as implantable extended-release devices, drug-eluting punctal plugs, polymer-based contact lenses, microneedle-injection devices, and microdosing technologies can then be followed by traditional or laser surgical procedures or a combination of both. One of the main factors fueling the market's growth is the rising incidence of glaucoma worldwide. Patients with diabetes and other eye conditions, such as Age-Related Macular Degeneration (AMD), cataract, and dry eye, are significantly more probable to develop glaucoma. Also, another factor driving the market growth is increasing technological advancements in the field of ophthalmology and rising product innovation and development is anticipated to create demand for the market.

The key factors projected to fuel the growth of the global glaucoma therapeutics market are the rising occurrences of blindness and the rising numbers of glaucoma patients. The International Agency for the Prevention of Blindness reports that in 2020, 80 million individuals have glaucoma, an increase of nearly 20 million from its 2010 data findings. Additionally, the rising geriatric population is anticipated to create a lucrative opportunity for the market during the forecast period. However, the drug recalls by major players stifled market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Glaucoma Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the well-developed medical infrastructure and rising prevalence of glaucoma in the region. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period, owing to factors such as the rising prevalence of diabetes, rising ocular disorders, and the growing number of blind and visually impaired people would create lucrative growth prospects for the Glaucoma Therapeutics market across Asia Pacific region.

Major market players included in this report are:

Deep Dive

Allergan Plc

Merck & Co., Inc.

Akorn Operating Company LLC

Bausch & Lomb Incorporated

Oculis S.A.

Teva Pharmaceuticals Industries Ltd

Alcon

Pfizer Inc.

Nanodropper, Inc.

Recent Developments in the Market:

• In May 2020, AbbVie Inc announced the acquisition of Allergan Plc. Through this AbbVie Inc. has been able to establish itself as a market leader in the glaucoma sector.
• In Dec. 2019, In Japan, Senju Pharmaceutical Co., Ltd. announced the launch of AIBETA, a combination drug for the treatment of glaucoma and hypertension.

Global Glaucoma Therapeutics Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Drug Class, Disease Indication, Distribution Channel, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

Beta Blockers

Prostaglandins Analogs

Alpha Adrenergic Agonists

Carbonic Anhydrase Inhibitors

Combination Drugs

By Disease Indication:

Open Angle Glaucoma

Angle Closure Glaucoma

By Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

RoLA

Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Glaucoma Therapeutics Market, by Region, 2019-2029 (USD Billion)
  • 1.2.2. Glaucoma Therapeutics Market, by Drug Class, 2019-2029 (USD Billion)
  • 1.2.3. Glaucoma Therapeutics Market, by Disease Indication, 2019-2029 (USD Billion)
  • 1.2.4. Glaucoma Therapeutics Market, by Distribution Channel, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Glaucoma Therapeutics Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Glaucoma Therapeutics Market Dynamics

• 3.1. Glaucoma Therapeutics Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising incidence of glaucoma
    • 3.1.1.2. Increasing technological advancements
  • 3.1.2. Market Challenges
    • 3.1.2.1. Drug recalls by major players
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising geriatric population

Chapter 4. Global Glaucoma Therapeutics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. Industry Experts Prospective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Glaucoma Therapeutics Market, by Drug Class

• 6.1. Market Snapshot
• 6.2. Global Glaucoma Therapeutics Market by Drug Class, Performance - Potential Analysis
• 6.3. Global Glaucoma Therapeutics Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
• 6.4. Glaucoma Therapeutics Market, Sub Segment Analysis
  • 6.4.1. Beta Blockers
  • 6.4.2. Prostaglandins Analogs
  • 6.4.3. Alpha Adrenergic Agonists
  • 6.4.4. Carbonic Anhydrase Inhibitors
  • 6.4.5. Combination Drugs

Chapter 7. Global Glaucoma Therapeutics Market, by Disease Indication

• 7.1. Market Snapshot
• 7.2. Global Glaucoma Therapeutics Market by Disease Indication, Performance - Potential Analysis
• 7.3. Global Glaucoma Therapeutics Market Estimates & Forecasts by Disease Indication 2019-2029 (USD Billion)
• 7.4. Glaucoma Therapeutics Market, Sub Segment Analysis
  • 7.4.1. Open Angle Glaucoma
  • 7.4.2. Angle Closure Glaucoma

Chapter 8. Global Glaucoma Therapeutics Market, by Distribution Channel

• 8.1. Market Snapshot
• 8.2. Global Glaucoma Therapeutics Market by Distribution Channel, Performance - Potential Analysis
• 8.3. Global Glaucoma Therapeutics Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
• 8.4. Glaucoma Therapeutics Market, Sub Segment Analysis
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Online Pharmacy

Chapter 9. Global Glaucoma Therapeutics Market, Regional Analysis

• 9.1. Glaucoma Therapeutics Market, Regional Market Snapshot
• 9.2. North America Glaucoma Therapeutics Market
  • 9.2.1. U.S. Glaucoma Therapeutics Market
    • 9.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
    • 9.2.1.2. Disease Indication breakdown estimates & forecasts, 2019-2029
    • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
  • 9.2.2. Canada Glaucoma Therapeutics Market
• 9.3. Europe Glaucoma Therapeutics Market Snapshot
  • 9.3.1. U.K. Glaucoma Therapeutics Market
  • 9.3.2. Germany Glaucoma Therapeutics Market
  • 9.3.3. France Glaucoma Therapeutics Market
  • 9.3.4. Spain Glaucoma Therapeutics Market
  • 9.3.5. Italy Glaucoma Therapeutics Market
  • 9.3.6. Rest of Europe Glaucoma Therapeutics Market
• 9.4. Asia-Pacific Glaucoma Therapeutics Market Snapshot
  • 9.4.1. China Glaucoma Therapeutics Market
  • 9.4.2. India Glaucoma Therapeutics Market
  • 9.4.3. Japan Glaucoma Therapeutics Market
  • 9.4.4. Australia Glaucoma Therapeutics Market
  • 9.4.5. South Korea Glaucoma Therapeutics Market
  • 9.4.6. Rest of Asia Pacific Glaucoma Therapeutics Market
• 9.5. Latin America Glaucoma Therapeutics Market Snapshot
  • 9.5.1. Brazil Glaucoma Therapeutics Market
  • 9.5.2. Mexico Glaucoma Therapeutics Market
  • 9.5.3. Rest of Latin America Glaucoma Therapeutics Market
• 9.6. Rest of The World Glaucoma Therapeutics Market

Chapter 10. Competitive Intelligence

• 10.1. Top Market Strategies
• 10.2. Company Profiles
  • 10.2.1. Deep Dive
    • 10.2.1.1. Key Information
    • 10.2.1.2. Overview
    • 10.2.1.3. Financial (Subject to Data Availability)
    • 10.2.1.4. Product Summary
    • 10.2.1.5. Recent Developments
  • 10.2.2. Allergan Plc
  • 10.2.3. Merck & Co., Inc.
  • 10.2.4. Akorn, Operating Company LLC
  • 10.2.5. Bausch & Lomb Incorporated
  • 10.2.6. Oculis S.A.
  • 10.2.7. Teva Pharmaceuticals Industries Ltd
  • 10.2.8. Alcon
  • 10.2.9. Pfizer Inc
  • 10.2.10. Nanodropper, Inc.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption